Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT
Sign Up to like & getrecommendations! Published in 2024 at "Neurology"
DOI: 10.1212/01.wnl.0001050932.32807.8a
Abstract: Objective The phase 3b ADAPT NXT study (NCT04980495) investigated the efficacy, safety, and tolerability of efgartigimod administered either every other week (Q2W) or in fixed cycle dosing regimens. Background Individualized dosing of efgartigimod, a human… read more here.
Keywords: week; q2w; adapt nxt; fixed cycle ... See more keywords